REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cell therapy tested in patients with advanced blood cancer
Disease control TerminatedThis early-stage study tested the safety of Descartes-15, a personalized cell therapy for multiple myeloma patients whose cancer returned or didn't respond to standard treatments. Researchers collected patients' own immune cells, engineered them to target cancer, and reinfused th…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New hope for Tough-to-Treat blood cancer?
Disease control TerminatedThis early-stage study tested a new drug, KRT-232, added to a standard three-drug combination for multiple myeloma that has come back or stopped responding to treatment. The main goals were to find the safest dose and see how well the body handles the four-drug combination. It in…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC